Skip to Content

'
Yesid Alvarado - Valero, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1994 Escuela de Medicina Juan N. Corpas, Bogotá, Colombia, MD, Medicine of Science

Postgraduate Training

7/2010-6/2011 Advanced Oncology-Hematology Drug Development Fellowship Program, The University of Texas Health Science Center San Antonio, San Antonio, TX
7/2009-6/2011 Hematology - Oncology Fellowship Program, The University of Texas Health Science Center San Antonio, San Antonio, TX
8/2006-8/2008 Leukemia Fellowship Program, The University of Texas MD Anderson Cancer Center, Houston, TX
8/2003-7/2006 Internal Medicine Residency Program, Texas Tech University Health Sciences Center, Lubbock, TX

Board Certifications

10/2012 American Board of Internal Medicine / Medical Oncology (ABIM)

Experience/Service

Other Appointments/Responsibilities

Clinical Instructor, The University of Texas Health Science Center San Antonio, San Antonio, TX, 9/2008-6/2009

Honors and Awards

2007 Oppenheimer Fellowship in Drug Development
2007 Travel Award recipient, American Society of Hematology (ASH)

Professional Memberships

American Society of Hematology (ASH)
Member, 8/2007-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Alvarado Y, Giles FJ, Swords RT. The PIM kinases in hematological cancers. Expert Rev Hematol 5(1):81-96, 2/2012. PMID: 22272708.
2. Alvarado Y, Mita MM, Vemulapalli S, Mahalingam D, Mita AC. Clinical Activity of Mammalian Target of Rapamycin Inhibitors in Solid Tumors. Targeted Oncology 6(2):69-94, 5/2011.
3. Santos F, Alvarado Y, Kantarjian H, Verma D, O’Brien S, Mattiuzzi G, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 1(117):982-91, 3/2011.
4. Vemulapalli S, Mita M, Alvarado Y, Sankhala K, Mita A. The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas. Targeted Oncology 6(1):29-39, 3/2011.
5. Alvarado Y, Swords R, Kelly KR, Giles J. Clinical activity of laromustine (Onrigin™) in hematologic malignancies. Expert Review of Hematology 2(5):481-488, 10/2009.
6. Alvarado Y, Kantarjian H, O’Brien S, Faderl S, Borthakur G, Burger J, Wierda W, Garcia- Manero G, Shan J, Cortes J. Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in Long-Term Outcome for Patients with Early Chronic Phase Chronic Myeloid Leukemia. Cancer 115(16):3709-18, 8/2009.
7. Swords R, Alvarado Y , Giles F. The Current Status of Biphenotypic Leukemia. Myeloproliferative Disorders in Practice 2(2), 9/2008.
8. Borthakur G, Alvarado Y, Ravandi-Kashani F , Cortes J, Estrov Z , Faderl S , Ferrajoli A , Garcia-Manero G, Thomas D, Verstovsek S , Wierda W , Bueso-Ramos C , Bekele N , Giles F. Phase 1 Study of XL119, a Rebeccamycin Analog, in Patients with Refractory Hematologic Malignancies. Cancer 113(2):360-6, 7/2008.
9. Alvarado Y, Cortes J. Emerging Role of Aurora Kinase inhibition in Chronic Myeloid Leukemia. Clinical Leukemia 1(6):325-327, 12/2007.
10. Alvarado Y, Welch MA, Swords R, Bruzzi J, Schelette E, Giles F. Plasma Cell Granuloma: A Case Report of Multiple Lesions in the Lung and Review of the Literature. American Journal of Medical Sciences 334(5):402-6, 11/2007.
11. Alvarado Y, Jumper C, Hardwicke F, D’Cunha N, Cobos E. Acquired Hemophilia: A Case Report of 2 Patients with Acquired Factor VIII Inhibitor Treated with Rituximab Plus a Short Course of Steroid and Review of the Literature. Clinical and Applied Thrombosis and Hemostasis 13(4):443-8, 10/2007.
12. Alvarado Y, Welch M, Swords R, Bruzzi J, Schelette E, Giles F. Nelarabine Activity in Acute Biphenotypic Leukemia. Leukemia Research 31(11):1600-1603, 5/2007.
13. Alvarado Y, Giles FJ. Ras as a therapeutic target in hematologic malignancies. Expert Opin Emerg Drugs 12(2):271-84, 5/2007. PMID: 17604501.
14. Alvarado Y, Apostolidou E, Swords R, Giles FJ. Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia. Expert Opin Emerg Drugs 12(1):165-79, 3/2007. PMID: 17355221.
15. Apostolidou E, Swords R, Alvarado Y, Giles FJ. Treatment of Acute Lymphoblastic Leukemia: A New Era? Drugs 67(15):2153-71, 1/2007.
16. Angulo F, Alvarado Y , Chokesuwattanaskul W, Roongsritrong C. Troponin I Elevation in a patient with Acute Severe Bronchospasm. The American Journal of the Medical Sciences 329(6), 6/2005.
17. Giles F, Fracasso P, Kantarjian H, Cortes J, Brown R, Verstovsek S, Alvarado Y, thomas D, Faderl S, Garcia - Manero G, Wright L, Samson T, Cahill A, Lambert P, Plunket W, Sznol M, DiPersio J, Gandhi V. Phase I and pharmacodynamic study of Triapine®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leukemia Research 27(12):1077-1083, 12/2003.
18. Tsimberidou AM, Kantarjian H, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O’Brien S, Albitar M, Keating MJ, Giles FJ. Fractionated Cyclophosphamide, Vincristine, Liposomal daunorubicin, and Dexamethasone plus Rituximab and Granulocyte-Macrophage-Colony Stimulating Factor (GM-CSF) Alternating with Methotrexate and cytarabine plus Rituximab and GM-CSF in Patients with Richter’s Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia. Cancer 97(7), 4/2003.
19. Alvarado Y,Tsimberidou AM, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemotherapy and Pharmacology 5(1):87-90, 1/2003.
20. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z, Kantarjian H, Giles F. Pilot study of pegylated Interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemotherapy and Pharmacology 5(1):81-86, 1/2003.
21. Alvarado Y, Bellm LA, Giles FJ. Oral Mucositis: time for more studies. Hematology 7:281-289, 1/2002.
22. Alvarado Y, Kantarjian H, Cortes JE, Apostolidou E, Bivins C, Giles FJ. Troxacitabine activity in extramedullary myeloid leukemia. Hematology 7(3):179-185, 1/2002.

Abstracts

1. Liu - Dumlao T, Kantarjian H, Quintas - Cardama A, Jabbour E, Burger J, Alvarado Y, Burton E, Trinh L, Ravandi F, Ferrajoli A, O'Brien S, Cortes J,. Clinical significance of myelosuppression associated with the use of Dasatinib and Nilotinib as initial therapy in chronic phase of Chronic Myeloid Leukemia. 53rd ASH Annual Meeting. Blood 118 (#2761), 11/2011.
2. Alvarado Y, Kantarjian H, Ravandi F, Luthra R, Borthakur G, Garcia - Manero G, Faderl S, Konopleva M, Estrov Z, Andreeff M, Cortes J. FLT3 Inhibitor treatment in FLT3-mutated AML is Associated with development of secondary FLT3-TKD mutations. 53rd ASH Annual Meeting. Blood 118, 11/2011.
3. Ault P, Kantarjian H, Bryan J, Prescot H, Alvarado Y , Fava C, Cortes J. Clinical use of imatinib plasma levels in patients with chronic myeloid leukemia. 48th ASH Annual Meeting. Blood 112:4255, 11/2008.
4. Alvarado Y, Kantarjian H, Verma D, Mattiuzzi G, Aribi A, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoiesis-stimulating agents (ESA) in patients (pts) with chronic myeloid leukemia (CML) treated with imatinib. 49th ASH Annual Meeting, 12/2007.
5. Alvarado Y, Kantarjian H, Faderl S, Burger J, Borthakur G, O’Brien S, Wierda W, Garcia-Manero G, Cortes J. Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in Long-Term Outcome for Patients (Pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML). 49th ASH Annual Meeting, 12/2007.
6. Alvarado Y, Kantarjian H, Freireich EJ, Garcia-Manero G, Ferrajoli A, Koller C, Estrov Z, Kornblau S, Laddie N, Smith L, Cortes J. Phase II dosing study of cytarabine chemotherapy in combination with cenersen (EL625) and idarubicin in refractory and relapsed acute myelogenous leukemia (AML). ASCO National Annual Meeting, 6/2007.
7. Alvarado Y, Brown R, DiPiersio J, Verstovsek S, Cortes J, O’Brien S, Sznol M, Kantarjian H, Fracasso P, Giles F. Phase I study of Triapine, a novel ribonuclotide reductase inhibitor (RRI), in patients with refractory hematologic malignancies. 44th ASH Annual Meeting. Leukemia Research 27(12):1077-1083, 12/2003.
8. Alvarado Y, Kantarjian H, Cortes J, Verstovsek S, Faderl S, Garcia-Manero G, Tsimberidou A, Sznol M, Giles F. Phase I Study of VNP40101M, a novel alkylating agent in patients with refractory hematologic malignancies. ASCO National Annual Meeting, 5/2003.
9. Waddelow T, Mattiuzzi G, Alvarado Y, Giles F, Estey E. Rate of infections Associated with Gemtuzumab (GO) vs. Non-Gemtuzumab Therapy in patients with Acute Myelogenous Leukemia (AML) or myelodysplastic Syndrome (MDS), 12/2001.
10. Waddelow T, Mattiuzzi G, Alvarado Y, Giles F, Estey E. Rate of infections Associated with Gemtuzumab (GO) vs. Non-Gemtuzumab Therapy in patients with Acute Myelogenous Leukemia (AML) or myelodysplastic Syndrome (MDS). 43rd ASH Annual Meeting, 12/2001.

Last updated: 4/30/2013